ASCO 2016

Transforming the Care of Patients With Thyroid Cancer

Transforming the Care of Patients With Thyroid Cancer

By

There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.

VP Biden Talks About the Role of CancerLinQ at ASCO 2016

VP Biden Talks About the Role of CancerLinQ at ASCO 2016

By

At the 2016 ASCO meeting, Vice President Joe Biden spoke about his vision for comprehensive data-sharing as part of the Cancer MoonShot initiative.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Immunotherapy Combination is Effective in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Survey Highlights Barriers to Global Data Sharing

Survey Highlights Barriers to Global Data Sharing

By

Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

By

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

Trastuzumab Biosimilar Comparable the Monoclonal Antibody for Advanced HER2+ Breast Cancer

By

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

Web Application Improves Follow-up in Patients With Advanced Lung Cancer

By

A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.

More Data Needed on Cancer Treatment Costs

More Data Needed on Cancer Treatment Costs

By

More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers.

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

By

Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

By

Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.

Participants Understand Implications of Multiplex Gene Testing for Inherited Cancer Risk

Participants Understand Implications of Multiplex Gene Testing for Inherited Cancer Risk

By

Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.

Large Germline Databases Needed to Mitigate Ethnic Disparities

Large Germline Databases Needed to Mitigate Ethnic Disparities

By

"In the absence of patient-matched germline data, large germline databases are required in analysis workflows to minimize false positive mutation calling and mitigate ethnic disparities," a study presented at the ASCO 2016 Annual Meeting concluded.

Telephone Disclosure of Genetic Tests for Cancer Susceptibility Can Increase Satisfaction

Telephone Disclosure of Genetic Tests for Cancer Susceptibility Can Increase Satisfaction

By

Results showed that telephone disclosure was not worse than in-person disclosure for general and state anxiety.

'Breaking Bad' Symptoms: Constipation, Fatigue, Peripheral Neuropathy, Nausea and Vomiting

'Breaking Bad' Symptoms: Constipation, Fatigue, Peripheral Neuropathy, Nausea and Vomiting

By

"Patients who feel better, live longer." And, to help patients feel better, clinicians need to provide optimal symptom management, said Eric Roeland, MD, GI Oncology & Palliative Care, UC San Diego Moores Cancer Center, San Diego, California, discussant for 4 poster presentations at the ASCO 2016 Annual Meeting.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

By

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

By

At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

By

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

By

Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.

Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer

Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer

By

Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

By

NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

By

In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.

No Benefit for Chemoradiotherapy vs Chemotherapy After Resectable Gastric Cancer

No Benefit for Chemoradiotherapy vs Chemotherapy After Resectable Gastric Cancer

By

First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma

By

Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

By

The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

By

Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.

Personalized Medicine Approach Not Straightforward in Glioblastoma

Personalized Medicine Approach Not Straightforward in Glioblastoma

By

The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

New WHO Glioma Classification Can 'Optimize Patient Treatment Going Forward'

New WHO Glioma Classification Can 'Optimize Patient Treatment Going Forward'

By

The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

By

Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs